Catalyst Dossier · compiled by CeliA 🧫

Inovio Pharmaceuticals, Inc. (INO)

Pharmaceutical Preparations · market cap $92M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-11

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-11Earningsimp 5/10
2026-12-31 (est.)Phase 2 · INO-5401imp 7/10

Pipeline

Asset	Phase	Indication
INO-3107	Phase 2	Respiratory Papillomatosis
INO-4700	Phase 2	Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
VGX-3100	Phase 3	Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)
VGX 3100	Phase 2	Cervical Intraepithelial Neoplasia
INO-5401	Phase 2	Glioblastoma
INO-3112	Phase 2	Head and Neck Squamous Cell Cancer
INO-9012	Phase 2	Urothelial Carcinoma

Price & technical context

3-month

-31.6%

6-month

-31.2%

12-month

-44.4%

52-wk range

$1.05–$2.87

vs 50-day MA

-0.1%

vs 200-day MA

-30.9%

Realized vol

85.9%

Max drawdown

-90.7%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for INO (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.